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Abstract
Purpose Better tools are needed to estimate local recurrence (LR) risk after breast-conserving surgery (BCS) for DCIS. The 
DCIS score (DS) was validated as a predictor of LR in E5194 and Ontario DCIS cohort (ODC) after BCS. We combined 
data from E5194 and ODC adjusting for clinicopathological factors to provide refined estimates of the 10-year risk of LR 
after treatment by BCS alone.
Methods Data from E5194 and ODC were combined. Patients with positive margins or multifocality were excluded. Identi-
cal Cox regression models were fit for each study. Patient-specific meta-analysis was used to calculate precision-weighted 
estimates of 10-year LR risk by DS, age, tumor size and year of diagnosis.
Results The combined cohort includes 773 patients. The DS and age at diagnosis, tumor size and year of diagnosis pro-
vided independent prognostic information on the 10-year LR risk (p ≤ 0.009). Hazard ratios from E5194 and ODC cohorts 
were similar for the DS (2.48, 1.95 per 50 units), tumor size ≤ 1 versus  > 1–2.5 cm (1.45, 1.47), age ≥ 50 versus < 50 year 
(0.61, 0.84) and year ≥ 2000 (0.67, 0.49). Utilization of DS combined with tumor size and age at diagnosis predicted more 
women with very low (≤ 8%) or higher (> 15%) 10-year LR risk after BCS alone compared to utilization of DS alone or 
clinicopathological factors alone.
Conclusions The combined analysis provides refined estimates of 10-year LR risk after BCS for DCIS. Adding information 
on tumor size and age at diagnosis to the DS adjusting for year of diagnosis provides improved LR risk estimates to guide 
treatment decision making.
Keywords Ductal carcinoma in situ · DCIS · Meta-analysis · Prognosis · Local recurrence · Genomic
Introduction
Ductal carcinoma in situ (DCIS) is a noninvasive breast 
cancer but some women will go on and develop invasive 
breast cancer [1]. Our inability to elucidate which DCIS 
lesions will progress to invasion and which ones will remain 
indolent culminate in recommendations that women with 
DCIS undergo treatment. Most women will be treated by 
breast-conserving surgery (BCS) followed by the adminis-
tration of whole breast radiotherapy (RT), which has been 
proven to lower the risk of local recurrence (LR) (DCIS or 
invasive) after BCS [2]. Subset analyses from randomized 
trials demonstrate a similar relative (50%) reduction in LR 
risk with RT, but the absolute benefit from RT is not uniform 
for all patients. Some women will derive no or a very small 
absolute benefit from RT, resulting in unnecessary expo-
sure to radiation and its potential toxicities (over-treatment), 
while in others the omission of RT may result in a higher 
risk of LR (and invasive LR) that might have been avoided 
by treatment (under-treatment) [3]. To reduce over-treatment 
and under-treatment of DCIS, ascertainment of more precise 
estimates of individualized LR risk after BCS is desirable 
to help clinicians and patients more accurately assess the 
risks of LR with the potential absolute benefits of treatment.
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The Oncotype DCIS score (DS) is a 12-gene expression 
assay based on the Oncotype DX Recurrence score [4]. The 
DS reports a numeric value ranging from 0 to 100 and a 
categorical risk group: low risk (0–38), intermediate risk 
(39–54) and high risk (55–100). The ECOG-ACRIN E5194 
(E5194) prospective cohort study initially reported the sig-
nificance of the DS as an independent predictor of LR in 
selected women treated by BCS alone [5–7]. More recently, 
the DS was validated as a predictor of LR in the Ontario 
population-based DCIS cohort [8]. Multivariable analyses 
from both studies found that in addition to the DS, age at 
diagnosis and tumor size were also significant predictors 
of LR; however, current estimates of local and invasive LR 
risks associated with the DS do not adjust for these effects.
The objective of this analysis is to combine the data 
from the E5194 (with extended 12-year follow-up data) 
and Ontario cohorts to provide refined and more precise 
estimates of recurrence risk after BCS alone for DCIS. We 
performed a patient-specific meta-analysis [9] to evaluate 
the impact of the DS alone, age at diagnosis and tumor size 
alone or integration of all three parameters, on the predicted 
10-year risks of LR and invasive LR. In addition, we report 
10-year local and invasive recurrence risk estimates for each 
DS risk group (low, intermediate, high) adjusting for the 
effects of age, tumor size and year of diagnosis to provide 
more accurate estimates of recurrence risk to aid treatment 
decision making following BCS for DCIS.
Methods
Patient cohorts
ECOG‑ACRIN E5194 cohort
The ECOG-ACRIN E5194 study was a prospective, non-
randomized clinical trial [5, 6]. There were two cohorts of 
patients: (1) low- or intermediate-grade DCIS, tumor size 
2.5 cm or smaller (Cohort 1; N = 561); or (2) high-grade 
DCIS, tumor size 1 cm or smaller (Cohort 2; N = 104). Treat-
ment for all patients included surgical excision (lumpec-
tomy) of the primary DCIS tumor with a minimum negative 
margin width ≥ 3 mm or no tumor on re-excision. Radiation 
treatment was not allowed. The study was amended in May 
2000 to allow adjuvant tamoxifen as optional.
Ontario DCIS cohort
The methods used to establish the Ontario DCIS cohort have 
been previously described [8, 10]. The population cohort 
includes 3303 cases with pure DCIS treated by BCS; 1658 
treated by BCS alone and 1662 by BCS + RT. We obtained 
tissue blocks in 1751 cases (N = 828, BCS alone; N = 923, 
BCS + RT); we calculated the DS in 571 cases treated by 
BCS alone with clear margins. Patients with missing tumor 
size had their tumor size imputed [11]. The study cohort 
for this analysis includes 446 individuals with pure DCIS 
treated by BCS alone (Fig. 1).
For both the E5194 and Ontario cohort studies, system-
atic, pre-defined pathology review was performed [12].
Patient‑specific meta‑analysis
Fixed-effects patient-specific meta-analysis [9] was used to 
determine the risk of any LR using information from the two 
DS studies. Based on a Cox proportional hazards framework, 
we estimated the patient-specific log cumulative hazard for 
each study, combined the estimates of the log cumulative 
hazard across studies by weighting each study estimate by 
the inverse of its variance and then conducted the appropri-
ate transformation to derive the risk estimate. This meth-
odology is based on the assumption that study cohorts are 
equal in their underlying level of risk, once differences in 
the characteristics of the cohort have been accounted for. For 
each study, we present hazard ratios (HR) (95% confidence 
intervals (CI)), the 10-year LR risk estimate for patients in 
the two cohorts and the average estimated risk within each 
DS group (low, intermediate, high), tumor size and age cat-
egory, along with the minimum and maximum risk possible 
values for DS results in each group.
The statistical significance of the independent contri-
butions of the DS and the clinicopathological covariates 
tumor size, age at diagnosis and year of surgery to the LR 
risk assessment was evaluated using meta-analysis likeli-
hood ratio tests that summed the likelihood ratio Chi-square 
statistics and their degrees of freedom across E5194 and 
Fig. 1  Study cohort
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Ontario cohort studies. The clinical significance of integrat-
ing DS result with tumor size and age in risk estimation for 
patients with year of surgery 2000 or later compared to DS 
result alone and to tumor size and age alone was evaluated 
using predictiveness curves [13] and, in particular, the pro-
portion of combined cohort patients with estimated 10-year 
LR risk ≤ 8, ≤ 10, and > 15%.
Results
Study cohort
The study cohort includes 327 patients from E5194 and 446 
patients from the Ontario cohort (N = 773). The median 
age (range) at diagnosis was 61 years (10th–90th percentile 
45–77) in E5194 cohort and 62 years (45–79) in the Ontario 
cohort. In E5194 cohort, tumor size was ≤ 1 cm in 260 
(79.5%) patients, the median DS was 25 and the median 
follow-up interval was 11.5 years (range: 0.2–15.9). In the 
Ontario cohort, 181 (40.6%) of cases had tumor size ≤ 1 cm, 
the median DS was 30 and median follow-up interval was 
9.8 years (range: 0.1–16.2). The proportion of patients 
with low- , intermediate- and high-risk scores were 70.3, 
16.2 and 13.5% in E5194 and 64.6, 16.1 and 19.3% in the 
Ontario cohort. Among 327 patients in the E5194 cohort, 
there were 53 LRs (27 invasive LRs). Among 446 patients 
in the Ontario DCIS cohort, there were 65 LRs (38 invasive 
LRs) (Table 1).
Multivariable analyses
Any local recurrence
Multivariable Cox models were fit separately to the data 
from each cohort. There was no significant difference in the 
(Breslow) baseline cumulative hazard estimate at 10 years 
between the two cohorts (Wald test p = 0.49). Furthermore, 
there was no significant difference in the HRs associated 
with each covariate between the two cohorts (p = 0.86) 
allowing for the two datasets to be combined for analysis.
In the E5194 cohort, an increase of 50 units in the DS 
(DS/50) was associated with a 2.5-fold increased hazard of 
LR (HR 2.48; 95% CI 1.29, 4.75). There was an increase 
in the hazard of LR associated with tumor size > 1–2.5 cm 
compared to ≤ 1 cm (HR 1.45, 95% CI 0.78, 2.69), and 
decreased hazard associated with age ≥ 50 years at diag-
nosis (HR 0.61, 95% CI 0.33, 1.11) and year of diagnosis 
2000 or later (HR 0.67, 95% CI 0.38, 1.17), although these 
effects did not achieve statistical significance. In the Ontario 
cohort, an increase in DS/50 was associated with a twofold 
increased hazard for LR (HR 1.95; 95% CI 1.14, 3.32). The 
hazard ratio for LR associated with tumor size > 1–2.5 cm 
was 1.47 (95% CI 0.82, 2.64) and 2.99 (95% CI 1.32, 6.76) 
for tumor size ≥ 2.5 cm compared to ≤ 1 cm. We observed 
Table 1  Patient characteristics E5194 (n = 327) Ontario 
cohort 
(n = 446)
Age at diagnosis
 Median (10th–90th percentile) 61 (45–77) 62 (45–79)
 < 50 years 66 (20.2%) 92 (20.6%)
 ≥ 50 years 261 (79.8%) 354 (79.4%)
Tumor size
 ≤ 1 cm 260 (79.5%) 181 (40.6%)
 > 1–2.5 cm 67 (20.5%) 238 (53.4%)
 > 2.5 cm 0 27 (6.1%)
Nuclear grade
 Low 29 (8.9%) 50 (11.2%)
 Intermediate 187 (57.2%) 267 (59.9%)
 High 111 (33.9%) 129 (28.9%)
DCIS score median (10th–90th percentile) 25 (8–58) 30 (5–63)
DCIS score risk group
 Low risk 230 (70.3%) 288 (64.6%)
 Intermediate risk 53 (16.2%) 72 (16.1%)
 High risk 44 (13.5%) 86 (19.3%)
Year of diagnosis
 1994–1999 147 (45.0%) 255 (57.2%)
 2000 or later 180 (55.0%) 191 (42.8%)
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decreased risks of LR associated with age ≥ 50 years at 
diagnosis (HR 0.61, 95% CI 0.33, 1.11) and year of diagno-
sis 2000 or beyond (HR 0.49, 95% CI 0.28, 0.87) (Table 2).
High nuclear grade was not significantly associated 
with the risk of LR in the E5194 (HR 0.64; 95% CI 0.33, 
1.23, p = 0.18) or the Ontario (HR 0.98; 95% CI 0.55, 
1.75, p = 0.95) cohorts (p = 0.40) (Table S-1). There were 
no significant two-way interactions among the covariates 
(p = 0.68).
Invasive local recurrence
A smaller number of covariates were used in the model 
for invasive local recurrence, in part because the number 
of invasive events was smaller (N = 65). Data for tumor 
size > 2.5 cm were only available for the Ontario cohort 
tumor size  ≤  2.5  cm and was not associated with an 
increased hazard of invasive LR (E5194 HR 0.91, 95% CI 
0.34–2.42; Ontario HR 1.17, 95% CI 0.56–2.46). Accord-
ingly, models for invasive LR include dichotomized tumor 
size (> 2.5 cm vs. ≤ 2.5 cm), the DS (DS/50 units), and year 
of diagnosis (2000 or later vs. before 2000) were fit sepa-
rately to each cohort. In the E5194 cohort, an increase of 
DS/50 was associated with a 3.02-fold (95% CI 1.28, 7.14) 
increased hazard of invasive LR and diagnosis in year 2000 
or later was associated with a decreased hazard of invasive 
LR (HR 0.92, 95% CI: 0.42,2.00). In the Ontario cohort, an 
increase in DS/50 (HR 2.18, 95% CI: 1.12, 4.27) and tumor 
size > 2.5 cm (HR 2.20, 95% CI 0.85, 5.65) were associated 
with an increased hazard of invasive LR. Although large 
tumor size did not achieve statistical significance, the mag-
nitude of the HR was considered too large to ignore and as 
such was included in the prediction models. Year of diagno-
sis 2000 or later was associated with a decrease in the hazard 
of invasive LR (HR 0.57, 95% CI 0.28, 1.20) (Table 3).
Predicting local recurrence risk
The model that included the DS, tumor size and age at diag-
nosis and year of diagnosis demonstrated improved predic-
tion of the 10-year risk of LR compared to a model based 
on the DS alone (p = 0.009) or one based solely on tumor 
size, age at diagnosis and year of diagnosis without the DS 
(p = 0.002). This indicates that the DS and the clinicopatho-
logical covariates each contribute independent prognostic 
information on the estimated 10-year risk of LR after BCS.
To assess and compare the clinical utility of each model 
(DS alone, tumor size and age at diagnosis alone or inte-
gration of all three parameters combined), we examined 
its ability to identify patients with a low estimated 10-year 
risk of LR (defined as 10-year LR risk ≤ 8%) and its abil-
ity to identify those with an estimated higher risk of LR 
(defined as 10-year LR risk > 15%) after treatment by BCS 
alone. We found that integrating the effects of the DS, 
tumor size and age at diagnosis identified a greater propor-
tion of cases with a low risk of LR compared to models 
based on the DS alone, or one based solely on tumor size 
and age at diagnosis alone (all models were adjusted for 
the effect of year of diagnosis of 2000 or later). The inte-
gration of all three covariates (DS, tumor size and age at 
Table 2  Multivariable Cox 
models for any local recurrence Effect ECOG 5194 Ontario DCIS cohort
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
DCIS score/50 2.48 (1.29, 4.75) 0.006 1.95 (1.14, 3.32) 0.014
Tumor size (cm)
 > 1–2.5 versus ≤ 1 1.45 (0.78, 2.69) 0.24 1.47 (0.82, 2.64) 0.19
 > 2.5 versus ≤ 1 – – 2.99 (1.32, 6.76) 0.009
Age at diagnosis (years)
 ≥ 50 versus < 50 0.61 (0.33, 1.11) 0.10 0.84 (0.48, 1.49) 0.55
Year of diagnosis
 2000 or later versus 
before 1999
0.67 (0.38, 1.17) 0.16 0.49 (0.28, 0.87) 0.016
Table 3  Multivariate Cox 
proportional hazards regression 
model for the development of 
invasive local recurrence after 
breast-conserving surgery alone
E5194 Ontario DCIS cohort
Effect HR (95% CI) p value HR (95% CI) p value
DCIS score/50 3.02 (1.28, 7.14) 0.012 2.18 (1.12, 4.27) 0.023
Tumor size
 > 2.5 versus ≤ 2.5 cm N/A 2.20 (0.85, 5.65) 0.10
Diagnosis in 2000 or later 0.92 (0.42, 2.00) 0.83 0.57 (0.28, 1.20) 0.14
363Breast Cancer Research and Treatment (2018) 169:359–369 
1 3
diagnosis) identified 25.9% of women with an estimated 
10-year risk LR ≤ 8% compared to 17.7% of cases based 
on the DS alone; the model based on tumor size and age at 
diagnosis alone did not identify any patients with a 10-year 
risk of LR ≤ 8% after BCS alone.
In addition, and importantly, the model integrating the 
effects of tumor size and age at diagnosis with the DS also 
identified more women (21.1%) with a predicted high risk 
of LR (defined as 10-year LR risk > 15%) compared to 
models based on the DS alone (which identified 18.4% 
of women at high risk of LR) or one based on tumor size 
and age at diagnosis alone (which identified only 10.9% 
of women at high risk of LR) (Table 4). Predictiveness 
curves plotting the estimated 10-year risk of LR after BCS 
alone against the proportion of patients with this risk or 
less are shown in Fig. 2. The curves suggest improved 
discrimination between high-risk and low-risk patients in 
the population with utilization of DS combined with age 
and tumor size.
Refined estimates of recurrence risk: combining the effects 
of age at diagnosis, tumor size and year of diagnosis 
with the DCIS score
Table 5 summarizes the estimated average 10-year risks of 
LR following BCS alone based on age at diagnosis, tumor 
size and DCIS risk group (risk estimates at the low and high 
DS limits of each risk group are also provided), adjusted for 
year of diagnosis 2000–2003. This demonstrates the impact 
of the DS on the risk of LR by age and tumor size. For exam-
ple, for women age ≥ 50 years with tumor size 1.1–2.5 cm 
and an intermediate risk DS, the average 10-year risk of 
LR is 13.9%, ranging from 12.8% for those with a DS of 
39 to 15.6% for those with a DS of 54. Overall, women 
age ≥ 50 years with tumor size ≤ 1 cm and a low-risk DS 
have an average 10-year risk of LR of 7.2% (ranging from 
5.3 to 10.0%) and those ≥ 50 years with tumors 1.1–2.5 cm 
have an average 10-year risk of LR of 10.1% (ranging from 
7.3 to 12.6%). For the same age and tumor size groups, a 
high-risk DS was associated with approximately a twofold 
increased risk of LR at 10 years compared to cases with a 
low-risk DS. Overall, women age ≥ 50 years with tumor 
size ≤ 1 cm and a high-risk DS have an average 10-year 
risk of LR of 14.6% (ranging from 12.9 to 23.1%) and 
those ≥ 50 years with tumors 1.1–2.5 cm have an average 
10-year risk of LR of 19.5% (ranging from 15.8 to 28.7%).
For patients with tumor size > 2.5 cm, we produced risk 
estimates using the HR from the Ontario cohort together 
with HRs for other factors estimated separately for each 
cohort [9]. Women with lesions > 2.5 cm had substan-
tially higher estimated 10-year risks of LR after BCS 
Table 4  Proportion of patients with predicted 10-year LR risk  ≤  8 
or > 15%
Model Proportion of cases and predicted 
10-year risk of LR
≤ 8% ≤ 10% > 15%
DCIS score, tumor size, 
age combined
25.9% 47.0% 21.1%
DCIS score 17.7% 45.1% 18.4%
Tumor size, age 0 44.1% 10.9%
Fig. 2  Predicted 10-year risk of 
local recurrence after breast-
conserving surgery alone for 
DCIS: a comparison of models 
based on the DCIS score, tumor 
size and age at diagnosis. The 
estimated 10-year risk of LR 
after BCS alone against the 
proportion of patients with 
this risk or less is shown. The 
model integrating the effects 
of the DCIS score, tumor size 
and age at diagnosis identified 
more women with low and high 
risks of LR compared to models 
based on the DS alone or tumor 
size and age at diagnosis alone
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alone ranging from 20.4% for those with a low-risk DS, 
age ≥ 50–48.6% for women age < 50 with a high-risk DS; 
however, there were only a few (N = 23) young women with 
a high-risk DS treated by BCS alone. Risk estimates for LR 
and invasive LR are shown in Fig. 3a–d.
The average estimated 10-year risks of invasive LR for 
tumor size ≤ 2.5 cm and a low- , intermediate- or high-
risk DS were 5.3% (3.6–7.4%), 8.5% (7.5–9.8%) and 12.1% 
(10.0–20.5%). The corresponding estimates based on tumor 
size > 2.5 cm and DS risk group were 11.6% (7.7–15.5%), 
17.1% (15.8–20.3%) and 26.2% (20.6–40.0%), but these esti-
mates are based on few cases (Table 6).
Discussion
This combined analysis provides refined estimates of the 
10-year risk of LR and invasive LR of DCIS lesions treated 
by BCS alone. Integrating the effects of tumor size and age 
at diagnosis with the DS provides improved prediction and 
substantially better separation of low-risk from high-risk 
patients than either DS alone or information based on tumor 
size and age alone (without the DS).
Treatment decision making relies on estimating an indi-
vidual’s risk of recurrence after BCS weighed against the 
potential benefits of treatment. Regression models estimate 
the relationships among individual variables and the likeli-
hood of developing LR. Predictiveness curves combine the 
effects of risk modeling with the distribution of the risk-
prediction covariates in the patient population [13]. They 
illustrate the range and distribution of risk estimates within 
populations and provide a way to compare the performance 
of different models. We compared the performance of three 
models in predicting the risk of LR at 10 years after treat-
ment by BCS alone with clear margins using data from the 
E5194 and Ontario cohorts; one model included the DS 
alone, one model was based on tumor size, age at diagnosis, 
and a third model combined all three parameters, adjusting 
for year of diagnosis. We found that integration of the effects 
of tumor size, age at diagnosis and year of diagnosis with the 
DS significantly improves LR risk prediction compared with 
estimates based on the DS alone or one based on tumor size, 
age and diagnosis year alone (without the DS).
The extent to which predicted risk estimates will influ-
ence treatment decision making relies on the thresholds of 
LR risk that determine if additional treatment is warranted. 
In this regard, models that best classify individuals at very 
low or high risk of recurrence have the greatest clinical util-
ity. We evaluated the ability of each model to predict cases 
at very low risk of LR (defined as 10-year risk of LR ≤ 8%) 
or those at high risk (defined as 10-year risk of LR > 15%) 
after BCS alone. The model integrating tumor size and age 
at diagnosis with the DS performed better at both extremes. 
The DS/tumor size/age model identified 25.9% of the cohort 
as having a 10-year LR risk ≤ 8%. By comparison, the DS 
alone classified only 17.7% of cases while the model based 
on tumor size and age alone did not identify any cases as 
having a 10-year LR risk ≤ 8%. This suggests that the DS 
adjusted for the effects of tumor size and age at diagnosis 
can help reduce over-treatment by identifying significantly 
more women with a very low risk of LR after treatment by 
BCS alone for whom the benefit of RT would be extremely 
small. If the threshold for additional treatment is (a 10-year 
LR risk of) > 10%, then almost half the cases in the cohort 
(47%) would avoid additional treatment. These are mostly 
women ≥ 50 years of age with lesions ≤ 1 cm and DS ≤ 38 
(68%) but they also include women ≥ 50 years of age with 
lesions 1–2.5 cm and DS ≤ 21 (23%) and women ≤ 50 years 
of age with lesions ≤ 1 cm and DS ≤ 17 (9%). Table 4 lists 
the average refined estimates of LR risk within DS groups 
and demonstrates the impact of each parameter on the 
10-year LR risk by DS risk group. Women ≥ 50 years of 
age at diagnosis with lesions ≤ 2.5 cm and a low-risk DS or 
those aged < 50 years at diagnosis and tumor size ≤ 1 cm 
and a low-risk DS had average estimated 10-year risks of 
LR < 10.2% following treatment by BCS alone.
Table 5  10-year risks of 
any local recurrence (DCIS 
or invasive) after breast-
conserving surgery alone by 
combinations of age, tumor size 
and DCIS score
a Average risk for E5194 and Ontario DCIS cohort patients in DCIS score groups
b Risks at boundaries of DCIS score groups
10-year risk of local recurrence (%)a  (rangeb) by DCIS score group
Tumor size (cm) Age (year) Low DCIS score (0–38) Intermediate 
DCIS score 
(39–54)
High DCIS score (55–100)
≤ 1 ≥ 50 7.2 (5.3–10.0) 11.3 (10.2–12.7) 14.6 (12.9–23.1)
< 50 10.2 (7.4–13.9) 15.8 (14.1–17.4) 19.6 (17.7–30.7)
1.1–2.5 ≥ 50 10.1 (7.3–12.6) 13.9 (12.8–15.6) 19.5 (15.8–28.7)
< 50 14.5 (10.1–17.2) 18.9 (17.4–21.1) 23.2 (21.4–37.2)
> 2.5 ≥ 50 20.4 (14.9–27.0) 29.1 (27.4–33.3) 41.1 (33.8–54.4)
< 50 30.2 (20.6–36.1) 39.5 (36.6–43.6) 48.6 (44.1–66.5)
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Fig. 3  a 10-year risk of any 
local recurrence (left panels) 
and invasive local recurrence 
(right panels) estimated from 
patient-specific meta-analysis, 
for patients with diagnosis in 
2000 or later, age ≥ 50 at diag-
nosis and tumor size ≤ 2.5 cm. 
b 10-year risk of any local 
recurrence (left panels) and 
invasive local recurrence (right 
panels) estimated from patient-
specific meta-analysis, for 
patients with diagnosis in 2000 
or later, age ≥ 50 at diagnosis 
and tumor size > 2.5 cm or 
unknown. c 10-year risk of any 
local recurrence (left panels) 
and invasive local recurrence 
(right panels) estimated from 
patient-specific meta-analysis, 
for patients with diagnosis in 
2000 or later, age < 50 at diag-
nosis and tumor size ≤ 2.5 cm. 
d 10-year risk of any local 
recurrence (left panels) and 
invasive local recurrence (right 
panels) estimated from patient-
specific meta-analysis, for 
patients with diagnosis in 2000 
or later, age < 50 at diagnosis 
and tumor size > 2.5 cm or 
unknown
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Fig. 3  (continued)
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In addition, we found that integrating the impact of tumor 
size and age at diagnosis with the DS performed better at 
predicting cases with a high risk of LR (> 15%) after BCS 
alone where additional treatment would be warranted [21.1% 
compared to 18.4% classified by the DS alone and only 11% 
classified using tumor size and age without the DS (Fig. 2)]. 
There were women in all categories of age at diagnosis and 
lesion size with estimated LR > 15%.
This analysis has several strengths. It was derived from a 
prospective cohort and a population-based cohort treated by 
BCS alone with negative margins, includes large numbers of 
annotated samples with expert pathology assessment and DS 
molecular testing; therefore, the risk model is generalizable 
to similar patients in the general population. The baseline 
risks of LR and the HRs associated with the clinicopatho-
logical parameters were similar in the two cohorts (Table 2), 
indicating it is appropriate to apply a combined analysis. 
LR risks have declined over time [14]; therefore, adjusting 
the risk estimates to reflect outcomes beyond year 2000 to 
provide more accurate prediction of expected outcomes of 
women treated in the current era.
This analysis has several limitations. The study popula-
tion includes few women (N = 37) with tumors > 2.5 cm 
treated by BCS alone (6% of Ontario cohort); therefore, risk 
estimates in women with DCIS lesions > 2.5 cm should be 
interpreted with caution.
This analysis does not account for the impact of tamox-
ifen. Approximately one-third of the E5194 and 17% of 
those > 65 years in Ontario cohort received tamoxifen. 
Tamoxifen was used more frequently by patients diagnosed 
in 2000 or later (48.9%) than patients diagnosed before 2000 
(15.0%). A sensitivity analysis of E5194 data was conducted 
to assess the effect of tamoxifen regression parameter esti-
mates. A multivariate model was fit with the DS, tumor 
size, age, diagnosis year and a time-dependent indicator for 
tamoxifen use (Table S-2). The values of the HRs are similar 
to those in the main analysis, indicating that tamoxifen use 
did not greatly influence the estimates in this study.
In summary, this combined analysis provides refined esti-
mates of the 10-year LR and invasive LR risk after treatment 
by BCS alone. Integrating the effects of tumor size and age 
at diagnosis with the DS provides improved prediction and 
better separation of very low-risk from high-risk patients 
(Table  6, Fig.  2). Specifically, these refined estimates 
identify a greater proportion of women with a 10-year LR 
risk ≤ 8% after BCS alone who could safely avoid additional 
treatment since the absolute benefit from additional inter-
ventions would be low and a greater proportion of women 
with a higher 10-year LR risk > 15% in whom efficacious 
treatments are needed to lower the risk of future recurrence. 
This can improve clinical decision making and the manage-
ment of DCIS patients by helping clinicians and patients 
more accurately weigh risk of recurrence with the potential 
benefits of treatment.
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